Patents by Inventor Franziska SIEGEL
Franziska SIEGEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416249Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: May 10, 2023Publication date: December 28, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Patent number: 11691986Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: December 21, 2021Date of Patent: July 4, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
-
Publication number: 20230064983Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: September 22, 2022Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20220378762Abstract: Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.Type: ApplicationFiled: April 22, 2020Publication date: December 1, 2022Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Franziska SIEGEL, Daniel KORR, Jens SCHRÖDER, Stephan SIEGEL, Heidi GREULICH, Bethany KAPLAN, Matthew MEYERSON
-
Publication number: 20220298157Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.Type: ApplicationFiled: April 22, 2020Publication date: September 22, 2022Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20220281892Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: January 12, 2022Publication date: September 8, 2022Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
-
Publication number: 20220267353Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: December 21, 2021Publication date: August 25, 2022Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
-
Publication number: 20220227729Abstract: The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 14, 2020Publication date: July 21, 2022Applicant: Bayer AktiengesellschaftInventors: Duy NGUYEN, Knut EIS, Jeremie Xavier MORTIER, Hans BRIEM, Clara CHRIST, Anders Roland FRIBERG, Benjamin BADER, Patrick STEIGEMANN, Volker BADOCK, Jens SCHRÖDER, Franziska SIEGEL, Dieter MOOSMAYER
-
Patent number: 11339157Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: GrantFiled: October 23, 2018Date of Patent: May 24, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Ulrich Klar, Knut Eis, Detlev Sülzle, Ulf Bömer, Daniel Korr, Kirstin Petersen, Ursula Mönning, Uwe Eberspächer, Dieter Moosmayer, Matthew Meyerson, Heidi Greulich, Bethany Kaplan, Hassan Youssef Harb, Phi Manh Dinh
-
Patent number: 11254690Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: March 22, 2018Date of Patent: February 22, 2022Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
-
Patent number: 11242356Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: March 22, 2018Date of Patent: February 8, 2022Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
-
Publication number: 20200347079Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: March 22, 2018Publication date: November 5, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
-
Publication number: 20200123174Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: March 22, 2018Publication date: April 23, 2020Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
-
Patent number: 10130633Abstract: The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(?O)— or —C(?O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.Type: GrantFiled: March 17, 2014Date of Patent: November 20, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Kai Thede, William Scott, Eckhard Bender, Stefan Golz, Andrea Hägebarth, Philip Lienau, Florian Puehler, Daniel Basting, Dirk Schneider, Manfred Möwes, Anja Richter, Ludwig Zorn, Ningshu Liu, Ursula Mönning, Franziska Siegel
-
Publication number: 20180148418Abstract: The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.Type: ApplicationFiled: May 2, 2016Publication date: May 31, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Philipp BUCHGRABER, Detlev SÜLZLE, Simon HOLTON, Eckhard BENDER, Volkhart LI, Ningshu LIU, Franziska SIEGEL, Philip LIENAU, Michaela BAIRLEIN, Franz VON NUSSBAUM, Simon Anthony HERBERT, Marcus KOPPITZ
-
Publication number: 20180042931Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturingType: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20180044306Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Patent number: 9884063Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: April 1, 2015Date of Patent: February 6, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Knut Eis, Jens Ackerstaff, Sarah Wagner, Daniel Basting, Stefan Golz, Eckhard Bender, Volkhart Min-Jian Li, Philip Lienau, Ningshu Liu, Franziska Siegel, Marcus Bauser, Detlev Sülzle, Simon Holton, Michaela Bairlein, Philipp Buchgraber, József Bálint
-
Publication number: 20180028507Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.Type: ApplicationFiled: February 16, 2016Publication date: February 1, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20170114070Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 18, 2015Publication date: April 27, 2017Inventors: Kai THEDE, Eckhard BENDER, William SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PUEHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER